Pictet Asset Management Sa Affimed N.V. Transaction History

Pictet Asset Management Sa

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$2.27 - $4.86 $828,840 - $1.77 Million	-365,128 Reduced 7.09%	4,787,520 $13.3 Million
Q1 2022 May 13, 2022	BUY	$3.69 - $5.65 $1.94 Million - $2.97 Million	525,190 Added 11.35%	5,152,648 $22.5 Million
Q4 2021 Feb 10, 2022	BUY	$5.37 - $7.07 $3.42 Million - $4.5 Million	636,342 Added 15.94%	4,627,458 $25.5 Million
Q3 2021 Nov 12, 2021	BUY	$5.54 - $7.51 $22.1 Million - $30 Million	3,991,116 New	3,991,116 $24.7 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Pictet Asset Management Sa, based on Form 13F filings with the SEC.

Stay updated on Pictet Asset Management Sa with notifications on news.